Does Mild Deficit for Patients with Stroke Justify the Use of Intravenous Tissue Plasminogen Activator?

Journal of Stroke and Cerebrovascular Diseases

Volumn 19, Issue 2, 2010, Pages 116-120

  Hassan, Ameer E ^a   Zacharatos, Haralabos ^b   Hassanzadeh, Bahareh ^a   El Gengaihy, Ahmed ^a   AlKawi, Ammar ^a   Shhadeh, Akram ^a   Kirmani, Jawad F ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Acute ischemic stroke; intravenous; outcome; tissue plasminogen activator

Indexed keywords

ALTEPLASE; PLACEBO;

ADULT; AGED; ARTICLE; BOLUS INJECTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDICATION; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT OUTCOME;

AGED; BRAIN ISCHEMIA; CLINICAL PROTOCOLS; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; EMERGENCY MEDICAL SERVICES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77049108711     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2009.03.019     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions among adults-United States, 1999. MMWR Morb Mortal Wkly Rep 50 (2001) 120-125
2. American Heart Association. Heart disease and stroke statistics-2005 update (2005), American Heart Association, Dallas (TX)
3. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: Pooled analysis of atlantis, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
5. Kimura K., Iguchi Y., Yamashita S., et al. Atrial fibrillation as an independent predictor for no early recanalization after IV-t-PA in acute ischemic stroke. J Neurol Sci 267 (2008) 57-61
6. Jain S.V., and Morton L.D. Ischemic stroke and excellent recovery after administration of intravenous tissue plasminogen activator. Pediatr Neurol 38 (2008) 126-129
7. Litwin T., Członkowska A., Kobayashi A., et al. Thrombolysis in acute ischemic stroke within 3 hours of symptom onset: A report of the first 100 cases. NeurolI Neurochir Pol 42 (2008) 1-5
8. Kwiatkowski T.G., Libman R.B., Frankel M., et al., NINDS rt-PA Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 340 (1999) 1781-1787
9. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes. The National Institute of Neurological Disorders and Stroke rt-PA stroke study experience. Ann Emerg Med 46 (2005) 243-252
10. Demchuk A.M., Tanne D., Hill M.D., et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology 57 (2001) 474-480
11. Molina C.A., Montaner J., Abilleira S., et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: A case-control study. Stroke 32 (2001) 2821-2827
12. Broderick J.P., Lu M., Kothari R., et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 31 (2000) 2335-2341
13. Baumann C.R., Baumgartner R.W., Gandjour J., et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke 37 (2006) 1332-1333
14. Smith E.E., Abdullah A.R., Petkovska I., et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 36 (2005) 2497-2499
15. Kapral M.K., Fang J., Hill M.D., et al. Sex differences in stroke care and outcomes: Results from the registry of the Canadian stroke network. Stroke 36 (2005) 809-814
16. Kent D.M., Price L.L., Ringleb P., et al. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: A pooled analysis of randomized clinical trials. Stroke 36 (2005) 62-65
17. Elkind M.S., Prabhakaran S., Pittman J., et al. Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke. Neurology 68 (2007) 842-848
18. Brott T., Adams Jr. H.P., Olinger C.P., et al. Measurements of acute cerebral infarction: A clinical examination scale. Stroke 20 (1989) 864-870
19. Van Swieten J.C., Koudstaal P.J., Visser M.C., et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19 (1988) 604-607
20. Barber P.A., Zhang J., Demchuk A.M., et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56 (2001) 1015-1020
21. Vaishnav A.G., Pettigrew L.C., and Ryan S. Telephonic guidance of systemic thrombolysis in acute ischemic stroke: Safety outcome in rural hospitals. Clin Neurol Neurosurg 110 (2008) 451-454
22. Martínez-Pérez M., Cánovas-Vergé D., and Carvajal-Díaz A. Fibrinolytic treatment with tissue plasminogen activator: Outcomes in clinical practice with a multidisciplinary model of intervention. Rev Neurol 45 (2007) 129-133 (abstr)
23. Uyttenboogaart M., Koch M.W., Koopman K., et al. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol 65 (2008) 607-611
24. Batmanian J.J., Lam M., Matthews C., et al. A protocol-driven model for the rapid initiation of stroke thrombolysis in the emergency department. Med J Aust 187 (2007) 567-570
25. Yoneda Y., Yamamoto S., Hara Y., et al. Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit. Clin Neurol Neurosurg 109 (2007) 567-570
26. Barroso B., Larrieu J.M., Morisset C., et al. Feasibility of stroke thrombolysis at Pau Hospital, France. [in French]. Presse Med 36 (2007) 859-866 (abstr)
27. Schwammenthal Y., Drescher M.J., Merzeliak O., et al. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: Initial Israeli experience. Isr Med Assoc J 6 (2004) 70-74
28. Heushmann P.U., Kolominsky-Rabas P.L., Roether J., et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 292 (2004) 1831-1938
29. Sylaja P.N., Cote R., Buchan A.M., et al., Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis in patients older than 80 years with acute ischemic stroke: Canadian alteplase for stroke effectiveness study. J Neurol Neurosurg Psychiatry 77 (2006) 826-829
30. Simon J.E., Sandler D.L., Warwick Pexman J.H., et al. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischemic stroke? The Calgary experience. Age Ageing 33 (2004) 143-149
31. Engelter S.T., Reichhart M., Sekoranja L., et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 65 (2005) 1795-1798
32. Muir K.W., Weir C.J., and Murray G.D. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke 27 (1996) 1817-1820
33. DeGraba L.B., Hallenbeck J.M., Pettigrew K.D., et al. Progression in acute stroke: Value of the initial NIH stroke scale score on patient stratification in future trials. Stroke 20 (1999) 1208-1212
34. Adams Jr. H.P., Davis P.H., Leira E.C., et al. Baseline NIH stroke scale score strongly predicts outcome after stroke: A report of the trial of org 10172 in acute stroke treatment (TOAST). Neurology 25 (1999) 126-131